Blood Purification Therapy to Prevent or Treat MOF

  • Hiroyuki Hirasawa
  • Arthur E. Baue


The concept of hemodialysis and peritoneal dialysis for renal failure, which has been so successful, has been expanded into a number of techniques caled blood purification. Plasmapheresis has a role in die management of refractory myasthenia gravis, Goodpasture syndrome, hemolytic uremia, and Guillain-Barré syndrome.1 There is no doubt that removal of toxic products from the blood, such as endotoxin and mediator cytokines, could help sick, injured and septic patients. A number of clinical trials have suggested benefit for patients with systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), and multiple organ failure (MOF). There are a number of clinical problems that could be helped by such techniques in addition to the removal of potassium, urea nitrogen, and creatinine for renal failure (see Chapter 36). Potential benefits include (1) removal of excess fluid contributing to heart failure, pulmonary edema, and impaired arterial and tissue oxygenation; (2) removal of humoral mediators of inflammation; (3) removal of endotoxin; (4) nutritional management; (5) correction of fluid, electrolyte, and acid-base balance; (6) support as an artificial liver (see Chapter 44).


Systemic Inflammatory Response Syndrome Multiple Organ Failure Continuous Renal Replacement Therapy Multiple Organ Dysfunction Syndrome Blood Purification 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ronco C, Brendolan Aj Bllomo R: Current technology for continuous renal replacement therapies. In: Ronco C, Bellomo R (eds) Critical Care Nephrology. Dordrecht, Kluwer Academic, 1998; 1269–1308.CrossRefGoogle Scholar
  2. 2.
    Hirasawa H, Sugai T, Ohtake Y, et al: Blood purification for prevention and treatment of multiple organ failure. World J Surg 1998; 20: 482–486.CrossRefGoogle Scholar
  3. 3.
    Baue AE, Hirasawa H: Editorial overview of the surgical patient. Curr Opin Crit Care 1997; 3: 279–285.CrossRefGoogle Scholar
  4. 4.
    Hanasawa K, Kodama M, Aoki H, et al: New treatment of severe sepsis in septic multiple organ failure patients by extracorporeal endotoxin removal with a polmyxin B immobilized fiber column. Surg Forum 1993; 44: 88–89.Google Scholar
  5. 5.
    Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994; 167: 412–417.PubMedCrossRefGoogle Scholar
  6. 6.
    Kodama M, Tani T, Maekawa K, et al: Endotoxin eliminating therapy in patients with severe sepsis-direct hemoperfusion using polymyxin B-immobilized fiber column. Jpn J Surg 1995; 96: 277–285.Google Scholar
  7. 7.
    Hirasawa H, Sugai T, Ohtake Y, et al: Continuous hemofiltration and hemodiafiltration in the management of multiple organ failure. Contrib Nephrol 1991; 93: 42–51.PubMedGoogle Scholar
  8. 8.
    Hirasawa H, Sugai T, Oda S, et al: Continuous hemodiafiltration (CHDF) removes cytokines and improves respiratory index (RI) and oxygen metabolism in patients with acute respiratory distress syndrome (ARDS). Crit Care Med 1998; 26: 294.CrossRefGoogle Scholar
  9. 9.
    Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis remove cytokines from the circulation of septic patients. Crit Care Med 1993; 21: 522–529.PubMedCrossRefGoogle Scholar
  10. 10.
    Schetz M, Ferdinande P, van den Berghe G, et al: Removal of proinflammatory cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med 1995; 21: 169–175.PubMedCrossRefGoogle Scholar
  11. 11.
    Hrasawa H, Sugai T, Oda S, et al: Continuous hemodiafiltration can remove humoral mediators from bloodstream of the patients with systemic inflammatory response syndrome and multiple organ failure. Blood Purif 1997; 15: 136–137.Google Scholar
  12. 12.
    Hffman JN, Deppisch R, Faist E, et al: Hemofiltration in human sepsis: evidence of elimination of immunomodulatory substances. Surg Forum 1994; 45: 69–71.Google Scholar
  13. 13.
    Bllomo R, Baldwin I, Cole L, Ronco C: Preliminary experience with high-volume hemofiltration in human septic shock. Kidney Int 1998; 54-I (Suppl 66): S182–S185.Google Scholar
  14. 14.
    Kine JA, Gordon BE, Williams C, et al: Large-pore hemodialysis in acute endotoxin shock. Crit Care Med 1999; 27: 588–596.CrossRefGoogle Scholar
  15. 15.
    Dainaut JA, Vinsonneau C, Journois D: Hemofiltration and left ventricular function in sepsis: mechanisms and clinical implications. Crit Care Med 1999; 27: 473–474.CrossRefGoogle Scholar
  16. 16.
    Oa S, Hirasawa H, Isono K: Tissue oxygen metabolism and cellular injury in patients with septic multiple organ failure. J Jpn Surg Soc 1993; 94: 556–563.Google Scholar
  17. 17.
    Reves JH, Butt WW: Blood filtration in children with severe sepsis: safe adjunctive therapy. Intensive Care Med 1995; 21: 500.CrossRefGoogle Scholar
  18. 18.
    Hirasawa H, Sugai T, Ohtake Y, et al: Energy metabolism and nutritional support in anuric multiple organ failure patients. In: Tanaka T, Okada A (eds) Anuric Multiple Organ Failure Patients. Amsterdam, Elsevier, 1990; 429–440.Google Scholar
  19. 19.
    Hirasawa H, Sugai T, Ohtake Y, et al: Continuous hemofiltration and hemodiafiltration in the management of multiple organ failure. Contrib Nephrol 1991; 93: 42.PubMedGoogle Scholar
  20. 20.
    Belomo R, Farmer M, Wright C, Parkin G, Boyce N: Treatment of sepsis-associated severe acute renal failure with continuous hemodiafiltration: clinical experience and comparison with conventional dialysis. Blood Purif 1995; 13: 246.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Hiroyuki Hirasawa
  • Arthur E. Baue

There are no affiliations available

Personalised recommendations